Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant Phase 3 for Acute Migraine
NCT04571060Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Zavegepant with Placebo (2 arms). Primary endpoints: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose and Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose. Started Oct 2020; status: completed.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04571060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571060.